JW Holdings Supplies Winnerf to Mongolia... First Export to Asian Market

Expectations for Expanding Exports to Other Countries

JW Holdings announced on the 28th that it will officially export the 3-chamber total parenteral nutrition solution 'Winnerf Central 736·1085ml (hereinafter Winnerf)' to AsiaPharma LLC in Mongolia.

JW Holdings, responsible for the global business of JW Group, signed an exclusive supply contract with AsiaPharma for Winnerf in the Mongolian market in December 2021.

Established in 2002, AsiaPharma is a leading pharmaceutical company that has imported and distributed various pharmaceuticals and medical devices for 21 years and also has experience in distributing local total parenteral nutrition solutions. In December last year, AsiaPharma obtained product approval for Winnerf from the Mongolian Ministry of Health and began local sales.

Winnerf, a total parenteral nutrition solution developed by JW Life Science, is a product that divides one container into three chambers, allowing easy mixing of nutrients such as purified fish oil, four types of lipids, amino acids, and glucose. It is characterized by a higher content of omega-3 and omega-6 fatty acids, which promote patients' immune enhancement and recovery compared to conventional total parenteral nutrition solutions.

In Korea, JW Pharmaceutical is responsible for sales. Since its domestic launch in 2013, it has maintained the number one position in the total parenteral nutrition solution market.

This is the first time JW Holdings is exporting Winnerf to the Asian market. It is expected that the export of Winnerf to Mongolia will accelerate exports to other Asian countries.

Meanwhile, JW Life Science, a subsidiary of JW Holdings, completed the expansion of the first domestic fully automated total parenteral nutrition solution production facility, 'TPN Line 3,' at its infusion solution factory located in Dangjin, Chungcheongnam-do, in October last year. With the full operation of 'TPN Line 3,' JW Life Science's maximum annual production capacity of total parenteral nutrition solutions increased by 37%, from 10.2 million units to 14 million units. The maximum annual production capacity of all infusion solutions, including total parenteral nutrition solutions, is 180 million units, the largest scale in Korea.

This content was produced with the assistance of AI translation services.